Skip to main navigation Skip to search Skip to main content

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

  • Chantal F. Stockem
  • , Alberto Gil-Jimenez
  • , Hamza Ali
  • , Jeroen van Dorp
  • , Nick van Dijk
  • , Maurits L. van Montfoort
  • , Maartje Alkemade
  • , Annegien Broeks
  • , Iris M. Seignette
  • , Erik Hooijberg
  • , Wim Brugman
  • , Rhianne Voogd
  • , Bas W. G. van Rhijn
  • , Laura S. Mertens
  • , Jeantine M. de Feijter
  • , Niven Mehra
  • , Antoine G. van der Heijden
  • , Richard P. Meijer
  • , Britt B. M. Suelmann
  • , Wouter Scheper
  • Lodewyk F. A. Wessels, Daniel J. Vis, Michiel S. van der Heijden
  • Netherlands Cancer Institute
  • University of Regensburg
  • Radboud University Nijmegen
  • Utrecht University
  • Delft University of Technology

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PURPOSE: In NABUCCO, the safety and efficacy of preoperative ipilimumab plus nivolumab were assessed in stage III urothelial cancer. Encouraging responses were achieved, and ipilimumab 3 mg/kg (ipilimumab-high) seemed more effective than ipilimumab 1 mg/kg (ipilimumab-low). We explored ipilimumab plus nivolumab response biomarkers and tumor microenvironment (TME) treatment dynamics. PATIENTS AND METHODS: Baseline formalin-fixed, paraffin-embedded tumor tissue was analyzed using PD-L1 IHC (n = 51) and whole-exome and transcriptome sequencing (both n = 53) and correlated with response. Baseline infiltration of CD8+ T cells (n = 51) and at cystectomy (n = 42) was examined. Single-cell RNA sequencing (scRNA-seq) of CD3+ T cells was conducted on on-treatment resection tissue of two responders to ipilimumab-high to explore the characteristics of CD8+ T cells within the TME. RESULTS: High tumor mutational burden and PD-L1 positivity were associated with response to ipilimumab plus nivolumab. Nonresponding patients exhibited increased expression of a TGFβ signature. We observed increased transcription of the g2m checkpoint and e2f target in responders to ipilimumab-high and enhanced transcription of IFN-α and IFN-γ hallmarks in responders to ipilimumab-low. CD8+TCF7+ T cells accumulated in the TME of responders to ipilimumab-high. scRNA-seq of CD8A+TCF7+ T cells demonstrated enhanced expression of IL7R, CCR7, GPR15, XCL1, SELL, and LEF1. CONCLUSIONS: Our data indicate that tumor mutational burden, PD-L1, and TGFβ are potential biomarkers for response to ipilimumab plus nivolumab in stage III urothelial cancer. An inflammatory TME might be relevant for responding to ipilimumab-low. We found that in responders to ipilimumab-high, TCF7+CD8+ T cells accumulated in the TME. scRNA-seq in two responders suggested that TCF7+CD8A+ T cells express genes associated with immunologic memory formation and T-cell homing.
Original languageEnglish
Pages (from-to)3897-3906
Number of pages10
JournalClinical cancer research
Volume31
Issue number18
DOIs
Publication statusPublished - 15 Sept 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study'. Together they form a unique fingerprint.

Cite this